Media stories about Argos Therapeutics (NASDAQ:ARGS) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Argos Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.1973710815529 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
ARGS traded up $0.10 during trading on Thursday, reaching $0.27. Argos Therapeutics has a 1-year low of $0.15 and a 1-year high of $10.40. The company has a debt-to-equity ratio of -1.31, a quick ratio of 1.80 and a current ratio of 1.80.
Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings data on Monday, April 2nd. The biopharmaceutical company reported ($1.05) earnings per share for the quarter. The firm had revenue of $1.67 million for the quarter.
Argos Therapeutics, Inc, an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.
Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.